You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Metastatic Urothelial Carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma Trial in Philadelphia (Enfortumab

Not yet recruiting
  • Urothelial Carcinoma
  • +2 more
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center - Philadelphia
Jun 27, 2023

Metastatic Urothelial Carcinoma Trial in Guangzhou (utidelone injection)

Recruiting
  • Metastatic Urothelial Carcinoma
  • utidelone injection
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
May 29, 2023

Urothelial Carcinoma Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 27, 2023

Metastatic Urothelial Carcinoma Trial in Québec (Bicalutamide 150 mg, Placebo)

Not yet recruiting
  • Metastatic Urothelial Carcinoma
  • Bicalutamide 150 mg
  • Placebo
  • Québec, Canada
    CHU de Québec - Université Laval
Sep 6, 2023

Metastatic Urothelial Carcinoma Trial in Tampa, Boston (Ipilimumab, Nivolumab, Sacituzumab govitecan)

Recruiting
  • Metastatic Urothelial Carcinoma
  • Tampa, Florida
    Moffitt Cancer Center
Jan 24, 2023

Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter Trial in

Recruiting
  • Urothelial Cancer
  • +3 more
  • Sacituzumab Govitecan (SG)
  • Enfortumab vedotin-ejfv (EV)
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 28, 2022

Metastatic Urothelial Carcinoma, Urothelial Tumors Trial (Coformulated favezelimab/pembrolizumab, Coformulated

Not yet recruiting
  • Metastatic Urothelial Carcinoma
  • Urothelial Neoplasms
  • Coformulated favezelimab/pembrolizumab
  • +3 more
  • (no location specified)
Apr 26, 2023

Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer Trial (OB-002)

Not yet recruiting
  • Metastatic Cancer
  • +5 more
  • (no location specified)
Jul 10, 2023

Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)

Not yet recruiting
  • Locally Advanced Urothelial Carcinoma
  • +3 more
  • (no location specified)
Sep 15, 2022

Urothelial Carcinoma Trial (disitamab vedotin, pembrolizumab, gemcitabine)

Not yet recruiting
  • Urothelial Carcinoma
  • disitamab vedotin
  • +4 more
  • (no location specified)
Jun 9, 2023

Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma Trial in Sacramento

Recruiting
  • Advanced Urothelial Carcinoma
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Jun 28, 2022

Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter

Recruiting
  • Locally Advanced Bladder Urothelial Carcinoma
  • +13 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jun 8, 2022

Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma Trial in

Recruiting
  • Advanced Bladder Urothelial Carcinoma
  • +23 more
  • Riverside, California
  • +8 more
Jul 16, 2022

Metastatic Urothelial Carcinoma Trial (Pembrolizumab (200mg), Pembrolizumab (400mg), Monitoring)

Not yet recruiting
  • Metastatic Urothelial Carcinoma
  • Pembrolizumab (200mg)
  • +2 more
  • (no location specified)
Sep 18, 2023

Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma Trial (BGB-A445, Tislelizumab)

Not yet recruiting
  • Urothelial Carcinoma
  • +2 more
  • (no location specified)
Dec 15, 2022

Urothelial Carcinoma Associated 1 RNA, Human Trial (Pembrolizumab, Cisplatin, Carboplatin)

Active, not recruiting
Has Results
  • Urothelial Carcinoma Associated 1 RNA, Human
  • Pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Metastatic Cancer, Urothelial Carcinoma Trial (avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin)

Not yet recruiting
  • Metastatic Cancer
  • Urothelial Carcinoma
  • avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin
  • (no location specified)
Dec 19, 2022

Carcinoma, Transitional Cell, HER-2 Gene Amplification Trial in Beijing (Trastuzumab)

Recruiting
  • Carcinoma, Transitional Cell
  • HER-2 Gene Amplification
  • Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Mar 31, 2022

Urothelial Carcinoma Trial in United States (Gemcitabine, Cisplatin, Ipilimumab)

Completed
Has Results
  • Urothelial Carcinoma
  • Duarte, California
  • +7 more
Jul 7, 2022

Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter

Recruiting
  • Locally Advanced Bladder Urothelial Carcinoma
  • +18 more
  • Los Angeles, California
  • +2 more
Jun 28, 2022

Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter

Not yet recruiting
  • Locally Advanced Bladder Urothelial Carcinoma
  • +31 more
  • Diagnostic Laboratory Biomarker Analysis
  • Nivolumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Metastatic Urothelial Carcinoma, Bladder Cancer Trial in Tampa, Atlanta, Salt Lake City (Cabozantinib, Pembrolizumab)

Recruiting
  • Metastatic Urothelial Carcinoma
  • Bladder Cancer
  • Tampa, Florida
  • +2 more
Jun 9, 2022

Kidney Cancer, Renal Cell Carcinoma, Clear Cell Carcinoma Trial in Dallas (13C-Glucose, 13C-Acetate, 13C-Lactate)

Recruiting
  • Kidney Cancer
  • +11 more
  • 13C-Glucose
  • +4 more
  • Dallas, Texas
    University of Texas Southwestern Medical Center
Dec 1, 2022

Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic

Recruiting
  • Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
  • +3 more
  • Cabozantinib S-malate
  • +3 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Aug 8, 2022

Urine Omics Predicting IO Therapy Responses in mUC Patients

Recruiting
  • Metastatic Urothelial Carcinoma
  • No intervention required
  • Taipei, Taiwan
    National Taiwan University Hospital
Dec 19, 2021